- Home
- DOX vs RPRX Comparison
DOX vs RPRX Comparison
Compare DOX & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOX
- RPRX
- Stock Information
- Founded
- DOX 1982
- RPRX 1996
- Country
- DOX United States
- RPRX United States
- Employees
- DOX N/A
- RPRX N/A
- Industry
- DOX EDP Services
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- DOX Technology
- RPRX Health Care
- Exchange
- DOX Nasdaq
- RPRX Nasdaq
- Market Cap
- DOX 10.2B
- RPRX 11.7B
- IPO Year
- DOX 1998
- RPRX 2020
- Fundamental
- Price
- DOX $85.70
- RPRX $30.30
- Analyst Decision
- DOX Strong Buy
- RPRX Strong Buy
- Analyst Count
- DOX 5
- RPRX 6
- Target Price
- DOX $101.20
- RPRX $41.67
- AVG Volume (30 Days)
- DOX 595.7K
- RPRX 3.8M
- Earning Date
- DOX 02-04-2025
- RPRX 02-13-2025
- Dividend Yield
- DOX 2.24%
- RPRX 2.76%
- EPS Growth
- DOX N/A
- RPRX 518.56
- EPS
- DOX 4.25
- RPRX 2.55
- Revenue
- DOX $5,004,989,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- DOX N/A
- RPRX $14.54
- Revenue Next Year
- DOX $4.75
- RPRX $10.94
- P/E Ratio
- DOX $19.99
- RPRX $11.88
- Revenue Growth
- DOX 2.40
- RPRX N/A
- 52 Week Low
- DOX $74.41
- RPRX $24.05
- 52 Week High
- DOX $94.04
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- DOX 52.84
- RPRX 75.65
- Support Level
- DOX $81.75
- RPRX $29.67
- Resistance Level
- DOX $85.50
- RPRX $31.09
- Average True Range (ATR)
- DOX 1.26
- RPRX 0.70
- MACD
- DOX 0.18
- RPRX 0.51
- Stochastic Oscillator
- DOX 86.43
- RPRX 86.63
About DOX Amdocs Limited
Amdocs Ltd is a provider of software and services to communications, cable and satellite, entertainment, and media industry service providers. The Company and its subsidiaries operate in one operating segment, providing software products and services for the communications, entertainment and media industry service being designed, develop, market, support, implement, and operate its open and modular cloud offering. The company offers business support systems, operational support systems, and managed services. Geographically, it derives a majority of revenue from North America and also has a presence in Europe and the Rest of the world.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.